Story
Braveheart Bio Files for $318.8 Million IPO to Fund Heart Drug Trials
Braveheart Bio Inc., a clinical-stage biopharmaceutical company, announced plans to raise as much as $318.8 million in an initial public offering. The proposed listing would support the development of its lead drug candidate for treating a prevalent genetic heart disease.
Offering Details
According to a filing with the U.S. Securities and Exchange Commission on Thursday, the San Francisco-based company plans to offer 18.8 million shares at a price range of $15 to $17 each. At the top end of this range, the IPO would give Braveheart Bio a market valuation of approximately $1.2 billion.
The company has applied to list its common stock on the Nasdaq Global Market under the ticker symbol BRVE. The offering is being managed by a syndicate of joint bookrunners including Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel, and Cantor.
Use of Proceeds and Pipeline
Braveheart Bio is focused on developing BHB-1893, a next-generation oral cardiac myosin inhibitor for treating obstructive and non-obstructive hypertrophic cardiomyopathy. The company in-licensed the compound from its originator, Jiangsu Hengrui Pharmaceuticals Co., Ltd., in September 2025.
AdProceeds from the IPO are expected to fund crucial late-stage clinical trials:
- LIONHEART-HCM: A global Phase 3 trial for obstructive hypertrophic cardiomyopathy, set to begin in the second half of 2026. Interim results are anticipated in the second half of 2027.
- NOBLEHEART-HCM: A global Phase 3 trial for the non-obstructive form of the disease, planned to start in the first half of 2027.
Investor Backing
The company, which is backed by venture capital firm a16z, has also received a significant signal of institutional interest. Fidelity Management & Research Company LLC has provided a non-binding indication of interest to purchase up to $75 million worth of shares at the IPO price, according to the filing.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.